Supporting references 1. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3:e420. 2. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, et al. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res. 2001;61:6350-5. 3. Dai B, Yoo SY, Bartholomeusz G, Graham RA, Majidi M, Yan S, et al. KEAP1dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res. 2013;73:5532-43. 4. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, et al. Wildtype but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 1992;52:2340-3. 5. Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Van Bockstaele DR, Vermeulen K, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys. 2003;57:1075-83. 6. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 2000;60:1009-13. 7. Das GC, Holiday D, Gallardo R, Haas C. Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett. 2001;165:147-53. 8. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22:7218-21. 9. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73:6289-98. 10. Cavazzoni A, Petronini PG, Galetti M, Roz L, Andriani F, Carbognani P, et al. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene. 2004;23:8439-46. Supporting figure legends Figure S1. siRNA#3 and siRNA#5 specifically reduce the protein levels of Nrf2 and HMOX1 without affecting ERK and p53. Figure S2. The protein levels of NRF2 and the phosphorylated form of the extracellular signal-regulated kinase (p-ERK; a readout of KRAS activation) in several lung cell lines. Cell lysates were subjected to immunoblot analysis with anti-Nrf2, anti-ERK and an antibody specific for phosphorylated ERK. Table S1. Cisplatin toxicity as a function of KRAS, NRF2, KEAP1, and P53. The response to cisplatin-mediated toxicity of the listed NSCLC was measured by functional impairment of mitochondria using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. LD50s are listed. The coding regions of NRF2 and KRAS were sequenced and the status of each gene is listed. The mutation information for KEAP1 and TP53 was obtained from the literature. The references can be found in the supporting references according to the numbers in the table. Figure S3. Identification of a TRE (TGCGTCA) in the promoter of NRF2. The different human NRF2 promoter constructs were cloned upstream of a luciferase reporter gene (the sites where primer pairs bind are illustrated). These constructs were co-transfected into HEK293 cells alone with an empty vector, KRASDN, KRASG12D or KRASWT expression vector for 48h. Dual luciferase activities were measured. The experiment was repeated three times, each with triplicate samples. Data are expressed as mean ± SEM (*p 0.05 Ctrl group vs. KRAS) (left panel). Figure S4. Larger images of the IHC analyses shown in Figure 2B. Figure S5. Larger images of the IHC analysis shown in Figure 5D, left panel. Figure S6. Larger images of the IHC analysis shown in Figure 5D, right panel. Table S2. The percentage of mice with adenocarcinomas from each group. Figure S7. The average number of lesions (AHH+adenomas vs. adenocarcinomas). Supporting Materials and Methods Construction of recombinant DNA molecules The KRASG12D expression vector was constructed by cloning a PCR-generated fragment containing the entire open reading frame of KRASG12D from the original template RCAS-KRASG12D purchased from Addgene (# 11549) and inserting into the EcoR I/Xho I sites of pcDNA 3.1 (Invitrogen), using the following primers: sense, AAGAATTCAGATCGATATGACTGAG; antisense, AACTCGAGAACTAGTGGATCCCCCG. The wildtype form of KRAS (KRASWT) without the mutation from G to A at the 12th amino acid position and dominant negative form (KRASDN) with the mutation from S to N at the 17th amino acid position in pcDNA 3.1 were constructed by PCR and standard recombinant DNA techniques. The sequences were confirmed by direct nucleotide sequencing. Deletion fragments of the NRF2 promoter sequence were amplified by PCR using a human genomic DNA extracted from human bronchial epithelium cells and then cloned into the Kpn I/Xho I sites of pGL4.22 (Promega). The positions of PCR primers are shown in Figure 3A. The primer sequences are as follows: F0, ACGTGGTACCGAAATTTGTAAAGAGTAAAC; F1, GAAGGGTACCATCTGTGGCGTGGTGGCTGC; F2, TCAGGGTACCTGCGAACACGAGCTGCCGGA; F3, TCAGGGTACCGCAGCTCCTACACCAACGCC; F4, TGGCGGTACCTTCCCGCCCCCGGACCGCGA; F5, CCGGGGTACCCGGAGGAGCCGCCGACGCAG; R1, GGACCTCGAGTTGGGGCTCCCCGACGGCGG; R2, CCAGCTCGAGTCCCAGCAGGCGGGGGACCT; R3, CTGTCTCGAGTGTGTTGGGGCTCCCCGACG; R4, GGTGCTCGAGGCGTCGGCGGCTCCTCCGGG; R5, GGCACTCGAGCGGGCCCTTCCTTCCCCCGC. The fragment named “TRE”, which is located from 267 to 273 nt in NRF2’s promoter sequence including a sequence similar to AP-1 recognition site (“TGCGTCA”), was purchased (Sigma), and inserted into the Kpn I/ Xho I sites of pGL4.22 after endrepairing and annealing the two oligos together. mRNA extraction and real-time quantitative reverse transcription-PCR (qRT-PCR) Total mRNA was extracted using TRIzol (Invitrogen) according to the manufacturer’s instructions. Using equal amounts of mRNA and the Transcriptor first-strand cDNA synthesis kit (Promega), cDNA was generated and used for real-time qRT-PCR. The following TaqMan probes were obtained from the universal probe library (Roche): human NRF2, #70; HMOX1, #25; GCLM, #18; and GAPDH, #25. Both the forward and the reverse primers for human NRF2, HMOX1, GCLM, AND GAPDH were synthesized by Sigma and the sequences were as follows: NRF2, ACACGGTCCACAGCTCATC (Forward) and TGTCAATCAAATCCATGTCCTG (Reverse); HMOX1, AACTTTCAGAAGGGCCAGGT (Forward) and CTGGGCTCTCCTTGTTGC (Reverse); GCLM, GACAAAACACAGTTGGAACAGC (Forward) and CAGTCAAATCTGGTGGCATC (Reverse) and GAPDH, CTGACTTCAACAGCGACACC (Forward) and TGCTGTAGCCAAATTCGTTGT (Reverse). The real-time PCR was performed as follows: 1 cycle of predenaturation (94°C for 5 min), 40 cycles of amplification (94°C for 10 s and 60°C for 20 s), and a cooling program of 50°C for 30 s. Reactions for each sample were done in duplicate, and the experiment was repeated three times. The data are expressed as relative mRNA levels and were normalized to GAPDH. Quantification of cDNA amount for Nrf2, Keap1, Nqo1, Akr1b10, Akr1c1, Gclm, Hmox1 and β-actin in each tissue sample was performed with KAPA SYBR FASR qPCR Kit (Kapa Biosystems). All primer sets were designed with Primer 3 free online software. The primers were synthesized by Sigma and the sequences were as follows: Nrf2, CTCAGCATGATGGACTTGGA (Reverse); Keap1, and Akr1c1, TCTTGCCTCCAAAGGATGTC (Reverse); Nqo1, (Forward) and (Reverse); (Reverse); Gclm, and Akr1b10, GGCCATGTCCTCCTCACTTA GGAGGCCATGGAGAAGTGTA GCACACAGGCTTGTACCTGA (Forward) GGTAGCGGCTCCATGTACTC AGACCTGGAAGCCACAGAAA AGAGGACTGCAGCACAGGTT (Reverse); and GATCGGCTGCACTGAACTG GGCAGTGTGACAGGTTGAAG (Forward) (Forward) (Forward) and TCCCATGCAGTGGAGAAGAT (Forward) and AGCTGTGCAACTCCAAGGAC GAGCCTGAATCGAGCAGAAC (Reverse); and β-actin, (Forward) and (Reverse); Hmox1, CTCGGCTTGGATGTGTACCT AAGGCCAACCGTGAAAAGAT (Forward) and GTGGTACGACCAGAGGCATAC (Reverse). The real-time PCR was performed as follows: 1 cycle of predenaturation (95°C for 3 min), 40 cycles of amplification (95°C for 5 s and 60°C for 20 s and 72°C for 5 s), melting curve (95°C for 5 s, 65°C for 1 min and 97°C continuous), and a cooling program of 40°C for 30 s. Mean crossing point (Cp) values and SEM were determined. Cp values were normalized to the respective crossing point values of mβ-actin reference gene. Data are presented as the fold change in gene expression compared to the control group. All reporter gene and RTPCR analyses were repeated in three independent experiments and in duplicates. Data are all shown as mean ± SEM. Immunoblot analysis For detection of protein expression in total cell lysates, cells were washed with phosphate-buffered salt (PBS) buffer and lysed with sample buffer (50 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 100 mM dithiothreitol (DTT), 0.1% bromophenol blue) after indicated treatment. For detection of protein expression in the lung tissue samples, tissues were homogenized in 1 x sample buffer (50 mM TrisHCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 100 mM dithiothreitol (DTT), and centrifuged at 12,000 g at 4°C for 15 min to move debris. Then lysates were boiled, sonicated, and used for electrophoresis and immunoblot.